tradingkey.logo

BRIEF-NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site

ReutersFeb 19, 2025 3:05 PM

- Nkgen Biotech Inc NKGN.O:

  • NKGEN APPOINTS DR. ANITA FLETCHER AS NATIONAL PRINCIPAL INVESTIGATOR FOR PHASE 2A TROCULEUCEL TRIAL EVALUATING MODERATE ALZHEIMER’S DISEASE WITH ADVENTHEALTH ORLANDO AS FIRST EAST COAST SITE

Source text: ID:nGNX9pTy5b

Further company coverage: NKGN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI